StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Kunal Parar, Choice Broking

BUYZydus Lifesciences Limited

byKunal Parar, Choice BrokingHorizon: NA (inferred Swing (≤2wk))25 Aug 2026via ET Now

Entry₹1,127.4Inferred
Target₹1,150
Total upside +2.00% (call closed)
Stop loss₹1,090-3.32% risk
Exit₹1,15026 Aug 2026, 2:50 pm
Target hit+2.00%0.00%upside left
Follow Kunal Parar for new calls(33% target hit, 39 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 1 active Swing call on ZYDUSLIFE

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Aug 2026
6 supporting1 neutral1 opposing
Supports the BUY call (6)

Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection

NewsNdtv-Profit·21 Aug · 4d ago

(opens in new tab)

Zydus Lifesciences gets USFDA approval for generic Ascorbic Acid Injection

NewsCnbc-Tv18·21 Aug · 4d ago

(opens in new tab)

Zydus Lifesciences Ltd received final approval from the USFDA for Ascorbic Acid Injection, including 180-days CGT exclusivity.

BSE · Company Update·21 Aug · 5d ago

(opens in new tab)

Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic

NSE · Press Release·11 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (1)

From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, Outlook

NewsNdtv-Profit·12 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target

NewsEt-Markets·12 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.